Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Role Of Fibroscan In Detecting Hepatic Fibrosis Induced By Methotrexate

The Role Of Fibroscan In Detecting Hepatic Fibrosis Induced By Methotrexate AbstractIntroduction: Liver represents the main place of drug metabolisation. Drugs and toxic substances reach the level of liver after absorption at gastro-intestinal level. Drug hepatotoxicity represents an important chapter of iatrogenic pathology, because the hepatic lesions induced by drugs include extremely diverse clinical, biological and histological expressions that can take the aspect of any form of acute or chronic hepatobiliary disease. Hepatic lesions induced by drugs (LHIM) represent a histological and/or biochemical alteration caused and attributed to the consumption of a drug. Hepatic elastography (Fibroscan) represents a noninvasive method of quantification of hepatic fibrosis.Material and method: We carried out a retrospective study and longitudinally prospective study that included a set of patients under treatment with Methotrexate, amounting to 76, divided into 2 subsets: a subset consisting of patients with hepatitis to Methotrexate, subset 1, of 23 patients, a subset of patients under treatment with Methotrexate but with normal hepatic samples, subset b, of 53 patients.Results: We carried out fibroscan at all the patients treated with Methotrexate, obtaining a medium score of fibrosis of 6.23 for the subset a with hepatitis at Methotrexate and of 5.33 for the subset b with normal hepatic samples. We made a correlation between the cumulated dose of Methotrexate and the change of hepatic samples.Conclusions: There is a significant correlation between hepatic fibrosis induced by Methotrexate and the cumulated dose of Methotrexate. The possibility of utilization of fibroscan which is a completely painless method, reproducible, for the monitoring of the treatment with Methotrexate both at patients with changed values of the hepatic tests as weir as those with normal values must be considered. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png ARS Medica Tomitana de Gruyter

The Role Of Fibroscan In Detecting Hepatic Fibrosis Induced By Methotrexate

Download PDF
4 pages

Loading next page...
 
/lp/de-gruyter/the-role-of-fibroscan-in-detecting-hepatic-fibrosis-induced-by-jtS2ZOV7Mp
Publisher
de Gruyter
Copyright
© by R. L. Craciun
ISSN
1841-4036
eISSN
1841-4036
DOI
10.1515/arsm-2017-0004
Publisher site
See Article on Publisher Site

Abstract

AbstractIntroduction: Liver represents the main place of drug metabolisation. Drugs and toxic substances reach the level of liver after absorption at gastro-intestinal level. Drug hepatotoxicity represents an important chapter of iatrogenic pathology, because the hepatic lesions induced by drugs include extremely diverse clinical, biological and histological expressions that can take the aspect of any form of acute or chronic hepatobiliary disease. Hepatic lesions induced by drugs (LHIM) represent a histological and/or biochemical alteration caused and attributed to the consumption of a drug. Hepatic elastography (Fibroscan) represents a noninvasive method of quantification of hepatic fibrosis.Material and method: We carried out a retrospective study and longitudinally prospective study that included a set of patients under treatment with Methotrexate, amounting to 76, divided into 2 subsets: a subset consisting of patients with hepatitis to Methotrexate, subset 1, of 23 patients, a subset of patients under treatment with Methotrexate but with normal hepatic samples, subset b, of 53 patients.Results: We carried out fibroscan at all the patients treated with Methotrexate, obtaining a medium score of fibrosis of 6.23 for the subset a with hepatitis at Methotrexate and of 5.33 for the subset b with normal hepatic samples. We made a correlation between the cumulated dose of Methotrexate and the change of hepatic samples.Conclusions: There is a significant correlation between hepatic fibrosis induced by Methotrexate and the cumulated dose of Methotrexate. The possibility of utilization of fibroscan which is a completely painless method, reproducible, for the monitoring of the treatment with Methotrexate both at patients with changed values of the hepatic tests as weir as those with normal values must be considered.

Journal

ARS Medica Tomitana – de Gruyter

Published: Feb 1, 2017

References

  • Expression and regulation of hepatic drug and bile acid transporters
    Lecureur
  • Hepatic secretion of conjugated drugs and endogenous substances
    Keppler
  • Hepatic canalicular membrane Expression and localization of the conjugate export pump encoded by the MRP cMRP cMOAT ) gene in liver
    Keppler
  • Mechanisms of hepatic transport of drugs : implications for cholestatic drug reactions
    Bohan
  • Molecular alterations in hepatocyte transport mechanisms in acquired cholestatic liver disorders
    Lee
  • Organic anion transporting polypeptides of the OATP family phylogenetic classification as OATP / SLCO superfamily new nomenclature and molecular / functional properties
    Hagenbuch